Trazodone composition for once a day administration
US7829120B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Sep 11, 2006 |
| Grant date | Nov 9, 2010 |
| Priority date | — |
| Expiry date | Mar 27, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention relates to a once a day formulation of trazodone or a trazodone derivative. The formulation contains trazodone or a trazodone derivative and a controlled release excipient so that, once administered orally, the trazodone or the trazodone derivative is maintained at a therapeutic plasma concentration from at least 1 hour to at least 24 hours after initial administration. After administration, the initial therapeutic action takes effect within the first hour and lasts at least about 24 hours. This therapeutic effect remains relatively and substantially stable for the remaining period of 24 hours. The formulations can be used for treating depression and/or sleeping disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.